← Back to Eris Lifesciences Ltd. overview
Eris Lifesciences Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹2,879 cr | ₹352 cr | ₹25.81 | ₹7,033 cr | ₹2,854 cr | 12.33% | 13.51% | 0.87x | 12.22% |
| FY2024 | ₹1,991 cr | ₹392 cr | ₹28.79 | ₹7,040 cr | ₹2,586 cr | 15.16% | 9.62% | 1.08x | 19.69% |
| FY2023 | ₹1,662 cr | ₹382 cr | ₹28.07 | ₹3,667 cr | ₹2,196 cr | 17.4% | 14.02% | 0.4x | 23% |
| FY2022 | ₹1,326 cr | ₹406 cr | ₹29.88 | ₹2,272 cr | ₹1,908 cr | 21.28% | 22.4% | 0.04x | 30.62% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.